- Market Capitalization, $K 437,585
- Shares Outstanding, K 215,559
- Annual Sales, $ 0 K
- Annual Income, $ -79,980 K
- 60-Month Beta 2.01
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 4.03
|Period||Period Low||Period High||Performance|
| || |
+0.36 (+20.45%)since 08/27/21
| || |
-0.74 (-25.87%)since 06/25/21
| || |
-0.33 (-13.47%)since 09/25/20
? Over 50% reduction in personnel
Investors need to pay close attention to ZIOPHARM (ZIOP) stock based on the movements in the options market lately.
Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (Nasdaq: ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual...
Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles
Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company's manufacturing facility and presentation of favorable preclinical data
Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provide a corporate update and discuss financial...
Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (Nasdaq: ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, today announced that Company management will...
- Highlighted distinctive cellular therapy program, market opportunity and value proposition
BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Thursday reported a loss of $21.6 million in its first quarter.
- Annual shareholder meeting planned for May 19, 2021
|Ziopharm Oncology IN|
|Bioshares Biotech Clinical Trial|
|Global X Genomics & Biotechnology ETF|
|Ishares Genomics Immunology and Healthcare ETF|
|S&P Biotech SPDR|
|Micro-Cap Ishares ETF|